APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

G-CSF Biosimilars

Compare research editions
View pricing & licenses

Selected research

Industry Research

G-CSF Biosimilars Industry Research Report 2026

Report ID 173993620519 December 2025125 pages

Choose your research edition.

Industry ResearchG-CSF Biosimilars Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal G-CSF Biosimilars Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal G-CSF Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal G-CSF Biosimilars Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal G-CSF Biosimilars Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global G-CSF Biosimilars market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for G-CSF Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for G-CSF Biosimilars is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for G-CSF Biosimilars is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of G-CSF Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Pfizer, GlaxoSmithKline, Bayer and Amgen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global G-CSF Biosimilars market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

G-CSF Biosimilars Market by Company

Sanofi

Johnson & Johnson

Novartis

Merck & Co.

Roche

Pfizer

GlaxoSmithKline

Bayer

Amgen

AbbVie

AstraZeneca

Gilead Science

G-CSF Biosimilars Segment by Type

Insulin

Human Growth Hormone

Granulocyte-Colony Stimulating Factor

Interferon

Monoclonal Antibodies

Erythropoietin

G-CSF Biosimilars Segment by Application

Chronic And Autoimmune Diseases

Growth Hormone Deficiencies

Blood Disorders

Oncology Diseases

G-CSF Biosimilars Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global G-CSF Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of G-CSF Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of G-CSF Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of G-CSF Biosimilars manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of G-CSF Biosimilars by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of G-CSF Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global G-CSF Biosimilars Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global G-CSF Biosimilars Sales (K Units) of Manufacturers (2021-2026) Table 7. Global G-CSF Biosimilars Sales Market Share by Manufacturers (2021-2026) Table 8. Global G-CSF Biosimilars Revenue of Manufacturers (2021-2026) Table 9. Global G-CSF Biosimilars Revenue Share by Manufacturers (2021-2026) Table 10. Global Market G-CSF Biosimilars Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global G-CSF Biosimilars Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of G-CSF Biosimilars, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of G-CSF Biosimilars, Product Type & Application Table 14. Global G-CSF Biosimilars Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global G-CSF Biosimilars by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sanofi Company Information Table 19. Sanofi Business Overview Table 20. Sanofi G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Sanofi G-CSF Biosimilars Product Portfolio Table 22. Sanofi Recent Developments Table 23. Johnson & Johnson Company Information Table 24. Johnson & Johnson Business Overview Table 25. Johnson & Johnson G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Johnson & Johnson G-CSF Biosimilars Product Portfolio Table 27. Johnson & Johnson Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Novartis G-CSF Biosimilars Product Portfolio Table 32. Novartis Recent Developments Table 33. Merck & Co. Company Information Table 34. Merck & Co. Business Overview Table 35. Merck & Co. G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Merck & Co. G-CSF Biosimilars Product Portfolio Table 37. Merck & Co. Recent Developments Table 38. Roche Company Information Table 39. Roche Business Overview Table 40. Roche G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Roche G-CSF Biosimilars Product Portfolio Table 42. Roche Recent Developments Table 43. Pfizer Company Information Table 44. Pfizer Business Overview Table 45. Pfizer G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Pfizer G-CSF Biosimilars Product Portfolio Table 47. Pfizer Recent Developments Table 48. GlaxoSmithKline Company Information Table 49. GlaxoSmithKline Business Overview Table 50. GlaxoSmithKline G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. GlaxoSmithKline G-CSF Biosimilars Product Portfolio Table 52. GlaxoSmithKline Recent Developments Table 53. Bayer Company Information Table 54. Bayer Business Overview Table 55. Bayer G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Bayer G-CSF Biosimilars Product Portfolio Table 57. Bayer Recent Developments Table 58. Amgen Company Information Table 59. Amgen Business Overview Table 60. Amgen G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Amgen G-CSF Biosimilars Product Portfolio Table 62. Amgen Recent Developments Table 63. AbbVie Company Information Table 64. AbbVie Business Overview Table 65. AbbVie G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. AbbVie G-CSF Biosimilars Product Portfolio Table 67. AbbVie Recent Developments Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. AstraZeneca G-CSF Biosimilars Product Portfolio Table 72. AstraZeneca Recent Developments Table 73. Gilead Science Company Information Table 74. Gilead Science Business Overview Table 75. Gilead Science G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Gilead Science G-CSF Biosimilars Product Portfolio Table 77. Gilead Science Recent Developments Table 78. Global G-CSF Biosimilars Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 79. Global G-CSF Biosimilars Sales by Region (2021-2026) & (K Units) Table 80. Global G-CSF Biosimilars Sales Market Share by Region (2021-2026) Table 81. Global G-CSF Biosimilars Sales by Region (2027-2032) & (K Units) Table 82. Global G-CSF Biosimilars Sales Market Share by Region (2027-2032) Table 83. Global G-CSF Biosimilars Revenue by Region (2021-2026) & (US$ Million) Table 84. Global G-CSF Biosimilars Revenue Market Share by Region (2021-2026) Table 85. Global G-CSF Biosimilars Revenue by Region (2027-2032) & (US$ Million) Table 86. Global G-CSF Biosimilars Revenue Market Share by Region (2027-2032) Table 87. North America G-CSF Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. North America G-CSF Biosimilars Sales by Country (2021-2026) & (K Units) Table 89. North America G-CSF Biosimilars Sales by Country (2027-2032) & (K Units) Table 90. North America G-CSF Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 91. North America G-CSF Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 92. Europe G-CSF Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Europe G-CSF Biosimilars Sales by Country (2021-2026) & (K Units) Table 94. Europe G-CSF Biosimilars Sales by Country (2027-2032) & (K Units) Table 95. Europe G-CSF Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe G-CSF Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 97. Asia Pacific G-CSF Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Asia Pacific G-CSF Biosimilars Sales by Country (2021-2026) & (K Units) Table 99. Asia Pacific G-CSF Biosimilars Sales by Country (2027-2032) & (K Units) Table 100. Asia Pacific G-CSF Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 101. Asia Pacific G-CSF Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 102. South America G-CSF Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. South America G-CSF Biosimilars Sales by Country (2021-2026) & (K Units) Table 104. South America G-CSF Biosimilars Sales by Country (2027-2032) & (K Units) Table 105. South America G-CSF Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 106. South America G-CSF Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 107. Middle East and Africa G-CSF Biosimilars Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Middle East and Africa G-CSF Biosimilars Sales by Country (2021-2026) & (K Units) Table 109. Middle East and Africa G-CSF Biosimilars Sales by Country (2027-2032) & (K Units) Table 110. Middle East and Africa G-CSF Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 111. Middle East and Africa G-CSF Biosimilars Revenue by Country (2027-2032) & (US$ Million) Table 112. Global G-CSF Biosimilars Sales by Type (2021-2026) & (K Units) Table 113. Global G-CSF Biosimilars Sales by Type (2027-2032) & (K Units) Table 114. Global G-CSF Biosimilars Sales Market Share by Type (2021-2026) Table 115. Global G-CSF Biosimilars Sales Market Share by Type (2027-2032) Table 116. Global G-CSF Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 117. Global G-CSF Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 118. Global G-CSF Biosimilars Revenue Market Share by Type (2021-2026) Table 119. Global G-CSF Biosimilars Revenue Market Share by Type (2027-2032) Table 120. Global G-CSF Biosimilars Price by Type (2021-2026) & (US$/Unit) Table 121. Global G-CSF Biosimilars Price by Type (2027-2032) & (US$/Unit) Table 122. Global G-CSF Biosimilars Sales by Application (2021-2026) & (K Units) Table 123. Global G-CSF Biosimilars Sales by Application (2027-2032) & (K Units) Table 124. Global G-CSF Biosimilars Sales Market Share by Application (2021-2026) Table 125. Global G-CSF Biosimilars Sales Market Share by Application (2027-2032) Table 126. Global G-CSF Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 127. Global G-CSF Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 128. Global G-CSF Biosimilars Revenue Market Share by Application (2021-2026) Table 129. Global G-CSF Biosimilars Revenue Market Share by Application (2027-2032) Table 130. Global G-CSF Biosimilars Price by Application (2021-2026) & (US$/Unit) Table 131. Global G-CSF Biosimilars Price by Application (2027-2032) & (US$/Unit) Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. G-CSF Biosimilars Distributors List Table 135. G-CSF Biosimilars Customers List Table 136. G-CSF Biosimilars Industry Trends Table 137. G-CSF Biosimilars Industry Drivers Table 138. G-CSF Biosimilars Industry Restraints Table 139. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. G-CSF Biosimilars Product Image Figure 5. Global G-CSF Biosimilars Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global G-CSF Biosimilars Market Size (2021-2032) & (US$ Million) Figure 7. Global G-CSF Biosimilars Sales (2021-2032) & (K Units) Figure 8. Global G-CSF Biosimilars Average Price (US$/Unit) & (2021-2032) Figure 9. Insulin Product Image Figure 10. Human Growth Hormone Product Image Figure 11. Granulocyte-Colony Stimulating Factor Product Image Figure 12. Interferon Product Image Figure 13. Monoclonal Antibodies Product Image Figure 14. Erythropoietin Product Image Figure 15. Chronic And Autoimmune Diseases Product Image Figure 16. Growth Hormone Deficiencies Product Image Figure 17. Blood Disorders Product Image Figure 18. Oncology Diseases Product Image Figure 19. Global G-CSF Biosimilars Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of G-CSF Biosimilars, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 G-CSF Biosimilars Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global G-CSF Biosimilars Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global G-CSF Biosimilars Sales by Region in 2025 Figure 25. Global G-CSF Biosimilars Revenue by Region in 2025 Figure 26. North America G-CSF Biosimilars Market Size by Country in 2025 Figure 27. North America G-CSF Biosimilars Sales Market Share by Country (2021-2032) Figure 28. North America G-CSF Biosimilars Revenue Market Share by Country (2021-2032) Figure 29. United States G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe G-CSF Biosimilars Market Size by Country in 2025 Figure 32. Europe G-CSF Biosimilars Sales Market Share by Country (2021-2032) Figure 33. Europe G-CSF Biosimilars Revenue Market Share by Country (2021-2032) Figure 34. Germany G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific G-CSF Biosimilars Market Size by Country in 2025 Figure 40. Asia Pacific G-CSF Biosimilars Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific G-CSF Biosimilars Revenue Market Share by Country (2021-2032) Figure 42. China G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. China Taiwan G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America G-CSF Biosimilars Market Size by Country in 2025 Figure 51. South America G-CSF Biosimilars Sales Market Share by Country (2021-2032) Figure 52. South America G-CSF Biosimilars Revenue Market Share by Country (2021-2032) Figure 53. Mexico G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Brazil G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa G-CSF Biosimilars Market Size by Country in 2025 Figure 57. Middle East and Africa G-CSF Biosimilars Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa G-CSF Biosimilars Revenue Market Share by Country (2021-2032) Figure 59. Turkey G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Saudi Arabia G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. UAE G-CSF Biosimilars Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Global G-CSF Biosimilars Sales Market Share by Type (2021-2032) Figure 63. Global G-CSF Biosimilars Revenue Market Share by Type (2021-2032) Figure 64. Global G-CSF Biosimilars Price (US$/Unit) by Type (2021-2032) Figure 65. Global G-CSF Biosimilars Sales Market Share by Application (2021-2032) Figure 66. Global G-CSF Biosimilars Revenue Market Share by Application (2021-2032) Figure 67. Global G-CSF Biosimilars Price (US$/Unit) by Application (2021-2032) Figure 68. G-CSF Biosimilars Value Chain Figure 69. G-CSF Biosimilars Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. G-CSF Biosimilars Industry Opportunities and Challenges

Scope & coverage.

Types
  • Insulin
  • Human Growth Hormone
  • Granulocyte-Colony Stimulating Factor
  • Interferon
  • Monoclonal Antibodies
  • Erythropoietin
Applications
  • Chronic And Autoimmune Diseases
  • Growth Hormone Deficiencies
  • Blood Disorders
  • Oncology Diseases
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co.
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • Gilead Science

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global G-CSF Biosimilars Market Size (2021-2032)
  4. 2.2.2 Global G-CSF Biosimilars Sales (2021-2032)
  5. 2.2.3 Global G-CSF Biosimilars Market Average Price (2021-2032)
  6. 2.3 G-CSF Biosimilars by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Insulin
  9. 2.3.3 Human Growth Hormone
  10. 2.3.4 Granulocyte-Colony Stimulating Factor
  11. 2.3.5 Interferon
  12. 2.3.6 Monoclonal Antibodies
  13. 2.3.7 Erythropoietin
  14. 2.4 G-CSF Biosimilars by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Chronic And Autoimmune Diseases
  17. 2.4.3 Growth Hormone Deficiencies
  18. 2.4.4 Blood Disorders
  19. 2.4.5 Oncology Diseases
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global G-CSF Biosimilars Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global G-CSF Biosimilars Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global G-CSF Biosimilars Revenue of Manufacturers (2021-2026)
  4. 3.4 Global G-CSF Biosimilars Average Price by Manufacturers (2021-2026)
  5. 3.5 Global G-CSF Biosimilars Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of G-CSF Biosimilars, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of G-CSF Biosimilars, Product Type & Application
  8. 3.8 Global Manufacturers of G-CSF Biosimilars, Established Date
  9. 3.9 Global G-CSF Biosimilars Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sanofi
  2. 4.1.1 Sanofi Company Information
  3. 4.1.2 Sanofi Business Overview
  4. 4.1.3 Sanofi G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sanofi G-CSF Biosimilars Product Portfolio
  6. 4.1.5 Sanofi Recent Developments
  7. 4.2 Johnson & Johnson
  8. 4.2.1 Johnson & Johnson Company Information
  9. 4.2.2 Johnson & Johnson Business Overview
  10. 4.2.3 Johnson & Johnson G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Johnson & Johnson G-CSF Biosimilars Product Portfolio
  12. 4.2.5 Johnson & Johnson Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis G-CSF Biosimilars Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Merck & Co.
  20. 4.4.1 Merck & Co. Company Information
  21. 4.4.2 Merck & Co. Business Overview
  22. 4.4.3 Merck & Co. G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck & Co. G-CSF Biosimilars Product Portfolio
  24. 4.4.5 Merck & Co. Recent Developments
  25. 4.5 Roche
  26. 4.5.1 Roche Company Information
  27. 4.5.2 Roche Business Overview
  28. 4.5.3 Roche G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Roche G-CSF Biosimilars Product Portfolio
  30. 4.5.5 Roche Recent Developments
  31. 4.6 Pfizer
  32. 4.6.1 Pfizer Company Information
  33. 4.6.2 Pfizer Business Overview
  34. 4.6.3 Pfizer G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Pfizer G-CSF Biosimilars Product Portfolio
  36. 4.6.5 Pfizer Recent Developments
  37. 4.7 GlaxoSmithKline
  38. 4.7.1 GlaxoSmithKline Company Information
  39. 4.7.2 GlaxoSmithKline Business Overview
  40. 4.7.3 GlaxoSmithKline G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 GlaxoSmithKline G-CSF Biosimilars Product Portfolio
  42. 4.7.5 GlaxoSmithKline Recent Developments
  43. 4.8 Bayer
  44. 4.8.1 Bayer Company Information
  45. 4.8.2 Bayer Business Overview
  46. 4.8.3 Bayer G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Bayer G-CSF Biosimilars Product Portfolio
  48. 4.8.5 Bayer Recent Developments
  49. 4.9 Amgen
  50. 4.9.1 Amgen Company Information
  51. 4.9.2 Amgen Business Overview
  52. 4.9.3 Amgen G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Amgen G-CSF Biosimilars Product Portfolio
  54. 4.9.5 Amgen Recent Developments
  55. 4.10 AbbVie
  56. 4.10.1 AbbVie Company Information
  57. 4.10.2 AbbVie Business Overview
  58. 4.10.3 AbbVie G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 AbbVie G-CSF Biosimilars Product Portfolio
  60. 4.10.5 AbbVie Recent Developments
  61. 4.11 AstraZeneca
  62. 4.11.1 AstraZeneca Company Information
  63. 4.11.2 AstraZeneca Business Overview
  64. 4.11.3 AstraZeneca G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 AstraZeneca G-CSF Biosimilars Product Portfolio
  66. 4.11.5 AstraZeneca Recent Developments
  67. 4.12 Gilead Science
  68. 4.12.1 Gilead Science Company Information
  69. 4.12.2 Gilead Science Business Overview
  70. 4.12.3 Gilead Science G-CSF Biosimilars Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Gilead Science G-CSF Biosimilars Product Portfolio
  72. 4.12.5 Gilead Science Recent Developments
5 Global G-CSF Biosimilars Market Scenario by Region
  1. 5.1 Global G-CSF Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global G-CSF Biosimilars Sales by Region: 2021-2032
  3. 5.2.1 Global G-CSF Biosimilars Sales by Region: 2021-2026
  4. 5.2.2 Global G-CSF Biosimilars Sales by Region: 2027-2032
  5. 5.3 Global G-CSF Biosimilars Revenue by Region: 2021-2032
  6. 5.3.1 Global G-CSF Biosimilars Revenue by Region: 2021-2026
  7. 5.3.2 Global G-CSF Biosimilars Revenue by Region: 2027-2032
  8. 5.4 North America G-CSF Biosimilars Market Facts & Figures by Country
  9. 5.4.1 North America G-CSF Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America G-CSF Biosimilars Sales by Country (2021-2032)
  11. 5.4.3 North America G-CSF Biosimilars Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe G-CSF Biosimilars Market Facts & Figures by Country
  15. 5.5.1 Europe G-CSF Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe G-CSF Biosimilars Sales by Country (2021-2032)
  17. 5.5.3 Europe G-CSF Biosimilars Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific G-CSF Biosimilars Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific G-CSF Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific G-CSF Biosimilars Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific G-CSF Biosimilars Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America G-CSF Biosimilars Market Facts & Figures by Country
  35. 5.7.1 South America G-CSF Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America G-CSF Biosimilars Sales by Country (2021-2032)
  37. 5.7.3 South America G-CSF Biosimilars Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa G-CSF Biosimilars Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa G-CSF Biosimilars Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa G-CSF Biosimilars Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa G-CSF Biosimilars Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global G-CSF Biosimilars Sales by Type (2021-2032)
  2. 6.1.1 Global G-CSF Biosimilars Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global G-CSF Biosimilars Sales Market Share by Type (2021-2032)
  4. 6.2 Global G-CSF Biosimilars Revenue by Type (2021-2032)
  5. 6.2.1 Global G-CSF Biosimilars Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global G-CSF Biosimilars Revenue Market Share by Type (2021-2032)
  7. 6.3 Global G-CSF Biosimilars Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global G-CSF Biosimilars Sales by Application (2021-2032)
  2. 7.1.1 Global G-CSF Biosimilars Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global G-CSF Biosimilars Sales Market Share by Application (2021-2032)
  4. 7.2 Global G-CSF Biosimilars Revenue by Application (2021-2032)
  5. 7.2.1 Global G-CSF Biosimilars Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global G-CSF Biosimilars Revenue Market Share by Application (2021-2032)
  7. 7.3 Global G-CSF Biosimilars Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 G-CSF Biosimilars Value Chain Analysis
  2. 8.1.1 G-CSF Biosimilars Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 G-CSF Biosimilars Production Mode & Process
  5. 8.2 G-CSF Biosimilars Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 G-CSF Biosimilars Distributors
  8. 8.2.3 G-CSF Biosimilars Customers
9 Global G-CSF Biosimilars Analyzing Market Dynamics
  1. 9.1 G-CSF Biosimilars Industry Trends
  2. 9.2 G-CSF Biosimilars Industry Drivers
  3. 9.3 G-CSF Biosimilars Industry Opportunities and Challenges
  4. 9.4 G-CSF Biosimilars Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst